FindTrial
Sign In

Comparison of CD10 as a marker for tumor behaviour in breast carcinoma patients

To study the utility of CD10 as an immunohistochemical marker for assessing tumor behaviour in comparison to established histopathological parameters in breast carcinoma patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/070594
Enrollment
50
Registered
2024-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: CD10: Application of CD10 in breast carcinoma patients Intervention2: NIL: NIL Intervention3: NIL: THIS IS AN OBSERVATIONAL STUDY AS THERE IS NO TREATMENT OF THE SUBJECTS INVOLVED. KIND

Sponsors

Dr Preeti Mishra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Female patients diagnosed with breast carcinoma on histopathological examination. 2.Women with breast carcinoma having no history of treatment. 3.Female patients presenting with breast carcinoma arising de novo. 4.All cases that underwent mastectomy/modified radical mastectomy (MRM) procedure, incisional biopsy, excisional biopsy, or tru-cut biopsy.

Exclusion criteria

Exclusion criteria: •Patients with lesions other than breast carcinoma i.e., benign breast tumors, myoepithelial tumors, mesenchymal tumors. •Patients with breast carcinoma who have received neoadjuvant chemotherapy. •Breast carcinoma in males.

Design outcomes

Primary

MeasureTime frame
The study aims to explore the significance of CD10 expression and its correlation with various histopathological parameters in breast carcinoma. Investigating the immunohistochemical presence of CD10 in tumor tissues, we seek to elucidate its potential role to know tumor behaviour.Timepoint: Primary outcome will be assessed at 3 months.—

Secondary

MeasureTime frame
To analyze the relationship between CD 10 expression with various histopathological parameters (tumor size, tumor grade, Lymphovascular invasion, Perineural invasion, tumor budding), pathological TNM staging & molecular immunophenotypes of carcinoma breast.Timepoint: Secondary outcome will be assessed at 6 months.—

Countries

India

Contacts

Public ContactDr Samarth Shukla

Jawaharlal Nehru Medical College (JNMC) Wardha

samarth21174@gmail.com8830267710

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026